Compass Therapeutics

Compass Therapeutics

Yahoo Finance • 2 months ago

Is Eli Lilly and Company (LLY) A Good Stock To Buy Now?

Is LLY a good stock to buy? We came across a bullish thesis on Eli Lilly and Company on Value & Momentum Portfolio’s Substack. In this article, we will summarize the bulls’ thesis on LLY. Eli Lilly and Company's share was trading at $987.0... Full story

Yahoo Finance • 2 months ago

Here is Why Eli Lilly (LLY) is One of the Best Stocks to Buy for the Next 15 Years

Eli Lilly and Company (NYSE:LLY) is one of the best stocks to buy for the next 15 years. On May 7, Eli Lilly executed its largest bond issuance to date, selling $9 billion in investment-grade debt to fund a recent surge in acquisitions. Th... Full story

Yahoo Finance • 2 months ago

Canaccord Maintains Buy Rating on Compass Therapeutics (CMPX)

Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the 10 Best Day Trading Penny Stocks to Buy. On April 28, 2026, Canaccord lowered its price target on Compass Therapeutics, Inc. (NASDAQ:CMPX) to $7 from $13 and maintained a Buy rating.... Full story

Yahoo Finance • 2 months ago

Micron initiated, Rambus downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Baird upgraded Old Dominion(ODFL) to Ne... Full story

Yahoo Finance • 2 months ago

Midday Fly By: Verizon reports ‘beat and raise,’ Shell to acquire ARC

The major averages were broadly lower amid stalled peace negotiations between the U.S. and Iran as well as new escalation in the Strait of Hormuz. Investors are also balancing continued strength in corporate earnings and AI-driven optimism... Full story

Yahoo Finance • 3 months ago

ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch

On February 17, 2026, ENAVATE Sciences GP, LLC disclosed a buy of 157,800 shares of Zenas BioPharma(NASDAQ:ZBIO), an estimated $5.19 million trade based on quarterly average pricing. ENAVATE Sciences added 157,800 shares of Zenas BioPharm... Full story

Yahoo Finance • 4 months ago

Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight

LAS VEGAS, March 2, 2026 /PRNewswire/ -- The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology ap... Full story

Yahoo Finance • 6 months ago

Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference

Compass Therapeutics BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced tha... Full story

Yahoo Finance • 7 months ago

Here Are Wednesday’s Top Wall Street Analyst Upgrades and Downgrades: American Eagle Outfitters, Equinix, Garmin, Honeywell, Uber, Wendy’s and More

Thinkstock Quick Read After a brutal Monday, investors were treated to a snap-back rally in stocks on Tuesday. All of the major indices and Cryptocurrencies finished the day higher on Tuesday as hopes for an interest rate cut remained po... Full story

Yahoo Finance • 7 months ago

Compass Therapeutics to Participate in Upcoming December Investor Events

BOSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will p... Full story

Yahoo Finance • 7 months ago

Compass Therapeutics Inc. (CMPX) is A Buy on Wall Street on Robust Pipeline Development

Compass Therapeutics Inc. (NASDAQ:CMPX) is a must-buy penny stock to buy now. On November 10, Pipe Sandler analyst Biren Amin reiterated that Compass Therapeutics Inc. (NASDAQ:CMPX) is a Buy and set a $12 price target. The positive stance... Full story

Yahoo Finance • 7 months ago

Eli Lilly inks $2.6B deal with South Korea's ABL Bio for bispecific antibodies

[3d rendering of Bispecific antibodies or BsAbs] Love Employee/iStock via Getty Images Eli Lilly has signed an agreement with ABL Biotech for access to the South Korean biotech's Grabody platform to develop bispecific antibodies that is w... Full story

Yahoo Finance • 8 months ago

Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Based on a continuing trend of decreased mortality in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC), the analyses of overall survival (OS) an... Full story

Yahoo Finance • 10 months ago

Compass Therapeutics to Participate in Upcoming September Investor Events

BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human dise... Full story

Yahoo Finance • 11 months ago

Compass Therapeutics prices $120 million public offering of common stock

BOSTON - Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage oncology-focused biopharmaceutical company with a market capitalization of $462 million and impressive year-to-date returns of 119%, announced Tuesday the pricing of an un... Full story

Yahoo Finance • 11 months ago

Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering

BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human dise... Full story

Yahoo Finance • 11 months ago

Compass Therapeutics Announces Proposed Public Offering

BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human dise... Full story

Yahoo Finance • 11 months ago

Compass Therapeutics stock holds Outperform rating at Raymond James

Investing.com - Raymond James maintained its Outperform rating and $9.00 price target on Compass Therapeutics (NASDAQ:CMPX) following the company’s second-quarter financial results and clinical trial updates. The clinical-stage biopharmace... Full story

Yahoo Finance • 11 months ago

Tesla and Monday Lead Market Cap Stock Movers on Monday

Monday’s trading session has brought significant movements across the board, with Tesla Motors (NASDAQ:TSLA) accelerating upwards, while software company Monday (MNDY) experienced a steep drop. The market has reacted to a mix of earnings... Full story

Yahoo Finance • 11 months ago

Compass Therapeutics rises after pipeline updates

[Cancer cells vis] koto_feja Shares of Compass Therapeutics (NASDAQ:CMPX [https://seekingalpha.com/symbol/CMPX]) added ~21% on Monday after the cancer drug developer, with its Q2 2025 results, announced a lower-than-expected number of mor... Full story